Leonide Saad

Company: Alkeus Pharmaceuticals

Job title: Chief Executive Officer

Seminars:

Phase 2 Trial of ALK-001 in Stargardt Disease and Treatment Indications for Dry AMD/GA 11:15 am

ALK-001 is a first in class inhibitor of vitamin A dimerization Results of a randomized, placebo-controlled, clinical trial indicates that ALK-001 has disease modifying ability on the progression of Stargardt Disease ALK-001 is also being tested in Geographic Atrophy associated with dry-AMD in a fully enrolled Phase 3 study.Read more

day: Day Two

Roundtables: Discussing Regulatory Challenges Across Different Stages of Dry AMD Therapeutics Development 8:00 am

Some of the biggest challenges when developing drug for dry AMD is understanding the regulatory landscape for all stages of drug development. This session facilitates discussions on a range of regulatory checkpoints including: Pre-IND Endpoint Designation Recruiting & Phase I Phase II & Phase IIIRead more

day: Day Two